{"name":"Regulus Therapeutics","slug":"regulus","ticker":"RGLS","exchange":"NASDAQ","domain":"regulusrx.com","description":"Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Jay P. Toole","sector":"Nephrology / RNA Therapeutics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":72000,"revenueGrowth":300,"grossMargin":0,"rdSpend":35367000,"netIncome":-46358000,"cash":84181000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"RG-101 patent cliff ($0.0B at risk)","drug":"RG-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RGLS4326","genericName":"RGLS4326","slug":"rgls4326","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"RGLS4326","genericName":"RGLS4326","slug":"rgls4326","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Regulus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Regulus Therapeutics reported its fourth quarter and full year 2023 financial results, with a net loss of $13.4 million for the quarter and $54.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Regulus Therapeutics Announces Collaboration with AstraZeneca to Develop RNA Therapeutics for Cardiovascular Diseases","summary":"Regulus Therapeutics announced a collaboration with AstraZeneca to develop RNA therapeutics for the treatment of cardiovascular diseases.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Regulus Therapeutics Announces Positive Topline Results from Phase 2 Clinical Trial of RG-125","summary":"Regulus Therapeutics announced positive topline results from a Phase 2 clinical trial of RG-125, a GalNAc-conjugated antisense oligonucleotide targeting the miR-21 gene for the treatment of NASH.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPVzc1RzVxVFJiWGFkbWNiZVhMT3NSTk11SVo4WlBKblByZXE5MVN5SHAyQllnVzU1WEtCVi1UMDhXMFZwaW1wTTBudHNyeFhSc0FkNlNLcTR2Z2RmOFFxZUhReno4YkR1SnNQZC15VXAxNkZRY3pWNW9xdTA5TDAtUERjVHJFMU1ManQ2cGlkVjZMZXdOVm9KbHNZa3o?oc=5","date":"2025-06-25","type":"pipeline","source":"Novartis","summary":"Novartis completes acquisition of Regulus Therapeutics - Novartis","headline":"Novartis completes acquisition of Regulus Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQTEw1emYtTS1rb18wRGpyeHpsTDcwNnY0ZFE2dzRCcTdxYVN0NTl0VjRldlpMU1hCOVdZZ0MzcFAyRzlFanRNaDNHUEFHTnlkUG4zWnNObFRkQVd4TkZFaVpLZGJDMmJOTVFpWllfZUJMYTN1SXN0N09IcWZRM2RGRHc5WmE0c2NKcUVWNkUyQVJaeWxfSUNsWHQtRkJLMjFIMXdYbEtFQVBKTU9rZWs3NktlVHpHRmRyQ2ZCYW5tSHZoUmNYS3Fj?oc=5","date":"2025-04-30","type":"deal","source":"PR Newswire","summary":"Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG - PR Newswire","headline":"Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVkFQbXFMM0hKdkVwcTItS2dsY3dZeWt0N1hyZ05PZHRmalZoVEo5TXh2THV0QWZoU3FUOWY3UmZWZWVRMlo2bW5iVjA2Z1FXZWNySzdjNXo5OWpOOG95VnhNOG9QaWNDWUY3dTBNWEdZNGEydmNQaVlYMFU0SHE4YUNKaUNZMm9Kb0V2VzBkRU5yWmxBNk4yeWZhMXF0bmxETkpjdzI1dUg2WERmQkFVMlNnTkFta0puaHk0?oc=5","date":"2025-04-30","type":"deal","source":"reuters.com","summary":"Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal - reuters.com","headline":"Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOeDI5RGpsaGl1Mnh1LWNMN0lYa0xpRTF4eVY5RlJKVnJsc1pBb3hFNkdqZzQwN2pWb0JhSGtLSEhaMmFwekhMNloyOXNyR29QbDBjeVRhbko5ZUc5aWZpb01LTWtraEhlS2tWY0QxeWJfUS0yRmJVakFXcnZDVmItbzBmUWw0U3dld2ZSVzFtU1hvRklZUEJuekhhWnZjTVp3RnoxQmVDU2ZaM0k?oc=5","date":"2025-04-30","type":"trial","source":"MedCity News","summary":"Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition - MedCity News","headline":"Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQnVZTml3UWdvV25hNWNmeDQxcURNRVo5TDFyQ1hMSDh6NENPTmlTblBmVGtIMHUyclctNFBWQlJhZTk2YjhfUHlfeEtPSjk4Q3Y0QTZtWnhDSWh5MzNqUXdPZll3dDRZVFBJdThkQXk4M01ZY2FVMnQ2MVZ0d0NBSE9hUmNnTThJZzBUbE9BZ01tNFJCbFBkdmZQQzNsbDNNNzhhck5nOGx4VjlodHdLb2JNRU94LUloS3ljN0xnMlA?oc=5","date":"2025-03-27","type":"trial","source":"Stock Titan","summary":"Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan","headline":"Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQS25JVnJaaFNRMk5rWXpHcU9qOTloRFUxWGhfdWNpb3JGNnI0UzlBTEZQN3dva1duOVhlX3VuLWxOcjlKeTJ3clNldmtNS21qNzBsQXdVOGIyXzlnckx5WDVkdHF0RnN6cnpCMmFZcGxTQk1Bd19aOXpFSm1NQld4YjAzZXJpelFVWHpWS2JabHpBWTU5VUFwNkk3TzdWQ1pmclh4ay1QdE1pZS1xOGVGUUI2N2Y4MmpOV1dvRW9VdmhvNUdmZWlSa2Q3ZWdLVkdENjB5SWpFT1VLVjlDTnM5b2tIMmQySHpnWVE?oc=5","date":"2025-03-13","type":"earnings","source":"PR Newswire","summary":"Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire","headline":"Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxNa1phWndfQ01pVzBHdks5dU51Szk1T1F5eXlJQnV2ZE05V1Jsa0w5ZVlTbURGYTVzRzhxb2g3b181dEh2elF4ZjhiX1NyS09ORXgwYTNWVEpkOTBlWlJ4ZW9XZloxM3gwX3BWdHB4TlViUDdxMnZZakVQb0pIWGtCUk5lSjJIZVBsdGVBNktUWTVobzZuZHFNNTlvakxuT2hXaHpxakFBMVJ3anhVbnpUZGxmcURnTmt4QmcxVVpJV0hua3RObW1rSGRrYUQ4dld2eEFOV08yYmxFWmE0YVJJUHdwLXlKOXVuQVNSbmlSNi1TQUppaGhZVzZhdnFZN2Z5VlhkV0t4dVA0X0V0Ti1hUmZma1U5V3VmVER0a2p4aGM1UmdzRmtuT1NfUXJxR0NhMHF1UE4yb0xWUFN6NFVZWQ?oc=5","date":"2025-01-29","type":"regulatory","source":"PR Newswire","summary":"Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) - PR Newswire","headline":"Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Di","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOdG52S3EtWmpyRFU3TTUzOUcwUFNPVlgtYkt3a21vanlsZEswUlNwV3BnZEN2bU94WnZYRTVfN0FxUWJUZzJhOE9HZk1wTi1PbzJaWURDM2FteXk0TUlpQmpGNHhEOHo0Q1liaWYyRFU4bktWdEFDdGdYQ2NOdnZ0SkEwc1pBNU9DTDZaQ1AtMEdNYzBTZUhPQXZFOERwRnVyUEhURi1PQi1wVDlXNE5NVW1JZ2ZGVTZqdW9oQW9aRjBBUjFJdG9yVy1IU3M0M09jeDV1NEhzZFc?oc=5","date":"2024-05-16","type":"pipeline","source":"PR Newswire","summary":"Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer - PR Newswire","headline":"Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer","sentiment":"neutral"}],"patents":[{"drugName":"RG-101","drugSlug":"miravirsen","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Alnylam Pharmaceuticals","Ionis Pharmaceuticals"],"therapeuticFocus":["Nephrology","RNA Therapeutics"],"financials":{"source":"sec_edgar+yahoo","revenue":72000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":72000,"period":"2017-12-31"},{"value":18000,"period":"2017-12-31"},{"value":18000,"period":"2017-09-30"},{"value":18000,"period":"2017-06-30"},{"value":18000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":35367000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-46358000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":84181000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}